TEVA Teva Pharmaceutical Industries Ltd
In Europe, marketing authorizations for pharmaceutical products may be obtained either through a centralized procedure involving the EMA, a mutual recognition procedure which requires submission of applications in other member states following approval by aso-called reference member state, a decentralized procedure that entails simultaneous submission of applications to chosen member states or occasionally through a local national procedure. During 2018, we continued to register products in the European Union, primarily using the decentralized procedure (simultaneous submission of applications to chosen member states). We continue to use, on occasion, the mutual recognition and centralized procedures.
Company profile
Ticker
TEVA
Exchange
Website
CEO
Kåre Schultz
Employees
Incorporated in
Location
Fiscal year end
Industry (SEC)
Pfizer • Merck & Co. • Allergan • Johnson & Johnson • Abbott Laboratories • Bristol Myers Squibb • Lilly Eli & Co • Warner Chilcott • AbbVie • Celgene ...
Former names
Teva Pharmaceutical Industries Limited
SEC CIK
Corporate docs
TEVA stock data
()
Calendar
7 May 20
8 Jul 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | 4.36B | 4.47B | 4.09B | 4.18B | |
| Net income | 25M | 75M | -307M | -671M | |
| Diluted EPS | 0.06 | ||||
| Net profit margin | 0.57% | 1.68% | -7.50% | -16.06% | |
| Operating income | 191M | 148M | -81M | -644M | |
| Net change in cash | -171M | 734M | -924M | 192M | |
| Cash on hand | 1.8B | 1.98B | 1.24B | 2.17B | |
| Cost of revenue | 2.29B | 2.03B | 2.44B | 2.44B |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 16.89B | 18.27B | 22.39B | 21.9B | |
| Net income | -1B | -2.47B | -16.45B | 311M | |
| Diluted EPS | |||||
| Net profit margin | -5.92% | -13.53% | -73.48% | 1.42% | |
| Operating income | -443M | -1.64B | -17.48B | 2.15B | |
| Net change in cash | 193M | 819M | -25M | -5.96B | |
| Cash on hand | 1.98B | 1.78B | 963M | 988M | |
| Cost of revenue | 9.35B | 9.98B | 11.24B | 10.04B |
Financial data from company earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 11 Jun 20 | Elstein Amir | Ordinary Shares | Option exercise | Aquire M | No | 0 | 17,621 | 0 | 2,016,269 |
| 11 Jun 20 | Elstein Amir | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | 0 | 17,621 | 0 | 0 |
| 11 Jun 20 | Crane Rosemary A | Ordinary Shares | Option exercise | Aquire M | No | 0 | 17,621 | 0 | 28,413 |
| 11 Jun 20 | Crane Rosemary A | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | 0 | 17,621 | 0 | 0 |
| 11 Jun 20 | Barer Sol J | Ordinary Shares | Option exercise | Aquire M | No | 0 | 31,388 | 0 | 254,300 |
| 11 Jun 20 | Barer Sol J | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | 0 | 31,388 | 0 | 0 |
| 11 Jun 20 | Peres Nechemia Jacob | Ordinary Shares | Option exercise | Aquire M | No | 0 | 17,621 | 0 | 17,621 |
| 11 Jun 20 | Peres Nechemia Jacob | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | 0 | 17,621 | 0 | 0 |
| 11 Jun 20 | Nisen Perry | Ordinary Shares | Option exercise | Aquire M | No | 0 | 17,621 | 0 | 17,621 |
| 11 Jun 20 | Nisen Perry | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | 0 | 17,621 | 0 | 0 |
Institutional ownership Q1 2020
13F holders |
Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
adapting, agent, alter, attract, Aviv, behavior, billiont, biopharmaceutical, book, BPCIA, China, communicable, consumption, created, Croatian, curb, dance, death, declared, detail, device, diagnosed, discretion, disrupted, disruption, duration, economy, efficacy, eighteen, emerge, emergence, emerging, employment, enjoined, ensure, ensuring, error, essential, evolving, experienced, experiencing, factor, feature, fibromyalgia, formatted, frame, franchise, fulfillment, guiding, hire, hope, Hospira, injury, Inline, insight, internationally, interrupting, Jr, judgement, judicial, kuna, largest, LIBOR, live, Louisiana, lyophilized, magnitude, Mexican, microscopic, monitorship, multiplier, nitrosamine, NOC, oncology, opposed, outbreak, overa, pack, Page, pandemic, personal, PM, post, postponed, precautionary, premium, prove, proximity, ranche, recession, redeem, redundancy, remotely, reset, rheumatoid, safe, safeguarding, safety, simultaneously, skilled, slightly, slower, society, spread, submission, supplementary, Tel, temporarily, temporary, therewith, tirelessly, tranche, transport, traumatic, travel, Ukraine, uncertain, unclear, uninterrupted, unprecedented, upcoming, upholding, vast, Virginia, volatility, Wegener, West, Western, widespread, workforce, workplace, wrongful, Wuhan, XBRL
Removed:
abiraterone, accessible, acting, ADHD, adjustment, advantage, Aggrenox, AKS, alternatively, amounting, announcement, anticompetitive, appointed, Argentinean, arguing, Asia, assigned, Attenukine, Baker, Barr, barring, Barry, bench, benchmark, BI, Boehringer, Bona, borrowing, canceled, car, CHF, chronic, CIS, close, closed, commence, commencement, commercializing, consumed, converted, corroborated, costly, counterparty, damage, de, decide, declined, deconsolidation, deferring, deliberately, denying, depreciable, derivatively, determining, devising, directly, director, docket, dose, educational, Elliot, ELS, enable, ER, estate, EUR, exemption, expedient, extend, felony, Fide, finance, focusing, fraud, fraudulent, GBP, governed, grantor, Grodko, guanfacine, harm, headcount, headroom, Helsinn, highest, hindsight, hip, identification, illegitimate, Improvement, inception, inflate, inflated, Ingelheim, initially, injection, injunction, INR, instructed, intervene, Intuniv, investigating, Island, issuing, JPY, knee, lacked, land, lease, leased, leasehold, leasing, lessee, listed, longstanding, manage, mandatory, Master, member, merit, methylphenidate, Mexico, mg, Montgomery, month, mutual, Nonemployee, nursing, observable, opening, opportunity, opted, optimization, orderly, originate, overlapping, overruled, OZ, Pacific, package, palonosetron, participate, pattern, Pension, periodically, permanent, pertaining, petition, PLN, point, practical, preclude, preferred, preliminary, presiding, prevailing, priority, proportion, proprietary, PTAB, punitive, real, reclassification, recognition, recognizing, recruit, redemption, refiled, relator, remained, renew, rent, rental, replaced, repurchased, request, rescissory, restart, retained, retroactive, retrospectively, return, reversal, Rhode, ROU, satisfied, scheme, seal, sham, Shire, short, shorter, slight, space, speaker, Statute, supplemental, supported, tam, team, terminate, topline, transfer, unadjusted, unchanged, underpinning, undiscounted, Unfair, unify, unpaid, unsealed, usage, variability, vehicle, voluntarily, warranty, whistleblower, Wisconsin, women, Zytiga
Financial reports
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
21 Feb 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19
10-K
2018 FY
Annual report
19 Feb 19
10-Q
2018 Q3
Quarterly report
1 Nov 18
10-Q
2018 Q2
Quarterly report
2 Aug 18
10-Q
2018 Q1
Quarterly report
3 May 18
10-K
2017 Q4
Annual report
12 Feb 18
Current reports
8-K
Departure of Directors or Certain Officers
9 Jun 20
8-K
Results of Operations and Financial Condition
7 May 20
8-K
Results of Operations and Financial Condition
12 Feb 20
8-K
Entry into a Material Definitive Agreement
25 Nov 19
8-K
Departure of Directors or Certain Officers
7 Nov 19
8-K
Results of Operations and Financial Condition
7 Nov 19
8-K
Regulation FD Disclosure
23 Oct 19
8-K
Departure of Directors or Certain Officers
2 Oct 19
8-K
Departure of Directors or Certain Officers
7 Aug 19
8-K
Results of Operations and Financial Condition
7 Aug 19
Registration and prospectus
F-6
Registration for ADRs (foreign)
13 Nov 18
424B3
Prospectus supplement
19 Apr 18
S-4
Registration of securities issued in business combination transactions
2 Apr 18
S-3/A
Shelf registration (amended)
28 Mar 18
S-3/A
Shelf registration (amended)
16 Feb 18
S-3
Shelf registration
29 Jan 18
S-8
Registration of securities for employees
7 Sep 17
S-8
Registration of securities for employees
12 Oct 16
S-8
Registration of securities for employees
3 Aug 16
424B5
Prospectus supplement for primary offering
19 Jul 16
Proxies
DEFA14A
Additional proxy soliciting materials
26 May 20
DEFA14A
Additional proxy soliciting materials
22 Apr 20
DEF 14A
Definitive proxy
22 Apr 20
PRE 14A
Preliminary proxy
19 Mar 20
DEFA14A
Additional proxy soliciting materials
16 Apr 19
DEF 14A
Definitive proxy
16 Apr 19
DEF 14A
Definitive proxy
25 Apr 18
DEFA14A
Additional proxy soliciting materials
25 Apr 18
Other
SD
Conflict minerals disclosure
31 May 19
EFFECT
Notice of effectiveness
4 Dec 18
SD
Conflict minerals disclosure
31 May 18
EFFECT
Notice of effectiveness
19 Apr 18
EFFECT
Notice of effectiveness
19 Apr 18
CORRESP
Correspondence with SEC
16 Apr 18
CORRESP
Correspondence with SEC
16 Apr 18
CORRESP
Correspondence with SEC
16 Apr 18
UPLOAD
Letter from SEC
9 Apr 18
UPLOAD
Letter from SEC
15 Aug 17
Ownership
4
TEVA PHARMACEUTICAL INDUSTRIES / Ronit Satchi-Fainaro ownership change
15 Jun 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Nechemia Jacob Peres ownership change
15 Jun 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Perry Nisen ownership change
15 Jun 20
4
TEVA PHARMACEUTICAL INDUSTRIES / ROBERTO MIGNONE ownership change
15 Jun 20
4
TEVA PHARMACEUTICAL INDUSTRIES / GERALD M LIEBERMAN ownership change
15 Jun 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Jean Michel Halfon ownership change
15 Jun 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Amir Elstein ownership change
15 Jun 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Rosemary A Crane ownership change
15 Jun 20
4
TEVA PHARMACEUTICAL INDUSTRIES / SOL J BARER ownership change
15 Jun 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Janet S. Vergis ownership change
11 Jun 20
Patents
APP
Utility
Use of Rasagiline for the Treatment of Restless Legs Syndrome
2 Jul 20
Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
GRANT
Utility
Solid state forms of trisodium valsartan: sacubitril
23 Jun 20
Solid state forms of trisodium vaisartan:sacubitril, processes for their preparation, pharmaceutical compositions containing such solid state forms and treatment methods using the pharmaceutical compositions are described.
APP
Utility
Processes for the Preparation of Niraparib and Intermediates Thereof
18 Jun 20
The present invention relates to novel procedures and novel intermediates useful in the synthesis of Niraparib or any salt thereof.
APP
Utility
Solid State Forms of Ixazomib Citrate
18 Jun 20
The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof.
GRANT
Utility
Processes for the preparation of sofosbuvir and intermediates thereof
9 Jun 20
Inventors: Vinod Kumar Kansal, Dhirenkumar Natvarial Mistry, Srinivas Achanta, Sundaraselvan Ariyamuthu, Miteshgir Kanchangir Goswami, Venkata Subbarao Yazali